Tumor Lysis Syndrome in Patients with Chronic Lymphocytic Leukemia Treated with BCL-2 Inhibitors: Risk Factors, Prophylaxis, and Treatment Recommendations
18 Feb, 2020 | 08:04h | UTCTumour lysis syndrome in patients with chronic lymphocytic leukaemia treated with BCL-2 inhibitors: risk factors, prophylaxis, and treatment recommendations – The Lancet Haematology (free registration required)